Target Information
| Target General Information | Top | |||||
|---|---|---|---|---|---|---|
| Target ID |
T99566
(Former ID: TTDI01220)
|
|||||
| Target Name |
Free radical (FRD)
|
|||||
| Gene Name |
NO-GeName
|
|||||
| Target Type |
Clinical trial target
|
[1] | ||||
| Disease | [+] 3 Target-related Diseases | + | ||||
| 1 | Ischemia [ICD-11: 8B10-8B11] | |||||
| 2 | Lung cancer [ICD-11: 2C25] | |||||
| 3 | Pancreatic cancer [ICD-11: 2C10] | |||||
| UniProt ID | ||||||
| Drugs and Modes of Action | Top | |||||
|---|---|---|---|---|---|---|
| Clinical Trial Drug(s) | [+] 3 Clinical Trial Drugs | + | ||||
| 1 | Disufenton sodium | Drug Info | Phase 3 | Ischemia | [2] | |
| 2 | RRx-001 | Drug Info | Phase 3 | Small-cell lung cancer | [3] | |
| 3 | SM-88 | Drug Info | Phase 2/3 | Pancreatic cancer | [4] | |
| Mode of Action | [+] 2 Modes of Action | + | ||||
| Modulator | [+] 2 Modulator drugs | + | ||||
| 1 | Disufenton sodium | Drug Info | [1] | |||
| 2 | RRx-001 | Drug Info | [5] | |||
| Stimulator | [+] 1 Stimulator drugs | + | ||||
| 1 | SM-88 | Drug Info | [6] | |||
| Drug Property Profile of Target | Top | |
|---|---|---|
| (1) Molecular Weight (mw) based Drug Clustering | (2) Octanol/Water Partition Coefficient (xlogp) based Drug Clustering | |
|
|
||
| (3) Hydrogen Bond Donor Count (hbonddonor) based Drug Clustering | (4) Hydrogen Bond Acceptor Count (hbondacc) based Drug Clustering | |
|
|
||
| (5) Rotatable Bond Count (rotbonds) based Drug Clustering | (6) Topological Polar Surface Area (polararea) based Drug Clustering | |
|
|
||
| "RO5" indicates the cutoff set by lipinski's rule of five; "D123AB" colored in GREEN denotes the no violation of any cutoff in lipinski's rule of five; "D123AB" colored in PURPLE refers to the violation of only one cutoff in lipinski's rule of five; "D123AB" colored in BLACK represents the violation of more than one cutoffs in lipinski's rule of five | ||
| References | Top | |||||
|---|---|---|---|---|---|---|
| REF 1 | NXY-059, a free radical--trapping agent, substantially lessens the functional disability resulting from cerebral ischemia in a primate species. Stroke. 2001 Jan;32(1):190-8. | |||||
| REF 2 | ClinicalTrials.gov (NCT00061022) Safety and Effectiveness of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke. U.S. National Institutes of Health. | |||||
| REF 3 | ClinicalTrials.gov (NCT03699956) RRx-001 Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond in Patients With Small Cell Lung Cancer (REPLATINUM). U.S. National Institutes of Health. | |||||
| REF 4 | ClinicalTrials.gov (NCT03512756) A Randomized Phase 2/3 Multi-Center Study of SM-88 in Patients With Metastatic Pancreatic Cancer. U.S. National Institutes of Health. | |||||
| REF 5 | Dinitroazetidines are a novel class of anticancer agents and hypoxia-activated radiation sensitizers developed from highly energetic materials. Cancer Res. 2012 May 15;72(10):2600-8. | |||||
| REF 6 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.